{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:48:53Z","timestamp":1791676133033,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07137-3","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:34:29Z","timestamp":1782308069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting response to hypomethylating agents in myeloid neoplasms: a robust model"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3729-4594","authenticated-orcid":false,"given":"Chao","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-qian","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"8","key":"7137_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G (2023) Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(8):1307\u20131325","journal-title":"Am J Hematol"},{"issue":"10","key":"7137_CR2","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.22.00437","volume":"41","author":"R Itzykson","year":"2023","unstructured":"Itzykson R, Santini V, Thepot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lubbert M, Sapena R et al (2023) Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network. J Clin Oncol 41(10):1888\u20131897","journal-title":"J Clin Oncol"},{"issue":"3","key":"7137_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ajh.26455","volume":"97","author":"MM Patnaik","year":"2022","unstructured":"Patnaik MM, Tefferi A (2022) Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(3):352\u2013372","journal-title":"Am J Hematol"},{"issue":"4","key":"7137_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562\u2013569","journal-title":"J Clin Oncol"},{"issue":"1","key":"7137_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00878-8","volume":"13","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Alkhateeb H, Gangat N (2023) Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J 13(1):108","journal-title":"Blood Cancer J"},{"issue":"2","key":"7137_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ajh.27564","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH et al (2025) Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax\u2009+\u2009hypomethylating agent. Am J Hematol 100(2):260\u2013271","journal-title":"Am J Hematol"},{"issue":"10","key":"7137_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104931","volume":"25","author":"N Radakovich","year":"2022","unstructured":"Radakovich N, Sallman DA, Buckstein R, Brunner A, Dezern A, Mukerjee S, Komrokji R, Al-Ali N, Shreve J, Rouphail Y et al (2022) A machine learning model of response to hypomethylating agents in myelodysplastic syndromes. iScience 25(10):104931","journal-title":"iScience"},{"key":"7137_CR8","doi-asserted-by":"publisher","unstructured":"Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP et al (2019) Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO Precis Oncol 3:PO.19.00119. Epub 2019 Sep 20. https:\/\/doi.org\/10.1200\/po.19.00119","DOI":"10.1200\/po.19.00119"},{"issue":"11","key":"7137_CR9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/ajh.25267","volume":"93","author":"D Idossa","year":"2018","unstructured":"Idossa D, Lasho TL, Finke CM, Ketterling RP, Patnaik MM, Pardanani A, Gangat N, Tefferi A (2018) Mutations and karyotype predict treatment response in myelodysplastic syndromes. Am J Hematol 93(11):1420\u20131426","journal-title":"Am J Hematol"},{"key":"7137_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","volume":"31","author":"M Duchmann","year":"2018","unstructured":"Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L et al (2018) Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents. EBioMedicine 31:174\u2013181","journal-title":"EBioMedicine"},{"issue":"1","key":"7137_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01580-z","volume":"15","author":"M Schmutz","year":"2023","unstructured":"Schmutz M, Zucknick M, Schlenk RF, Mertens D, Benner A, Weichenhan D, Mucke O, Dohner K, Plass C, Bullinger L et al (2023) Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen. Clin Epigenetics 15(1):171","journal-title":"Clin Epigenetics"},{"issue":"3","key":"7137_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","volume":"20","author":"A Unnikrishnan","year":"2017","unstructured":"Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V et al (2017) Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes. Cell Rep 20(3):572\u2013585","journal-title":"Cell Rep"},{"issue":"1","key":"7137_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11413-4","volume":"10","author":"T Oellerich","year":"2019","unstructured":"Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, Schliemann C, Bohnenberger H, Angenendt L, Hartmann W et al (2019) Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. Nat Commun 10(1):3475","journal-title":"Nat Commun"},{"issue":"9","key":"7137_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc3343","volume":"12","author":"AH Shih","year":"2012","unstructured":"Shih AH, Abdel-Wahab O, Patel JP, Levine RL (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12(9):599\u2013612","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7137_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/leu.2013.269","volume":"28","author":"F Traina","year":"2014","unstructured":"Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O\u2019Keefe CL et al (2014) Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 28(1):78\u201387","journal-title":"Leukemia"},{"issue":"5","key":"7137_CR16","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/leu.2011.342","volume":"26","author":"KH Metzeler","year":"2012","unstructured":"Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci G (2012) DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 26(5):1106\u20131107","journal-title":"Leukemia"},{"issue":"4","key":"7137_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00277-016-2912-7","volume":"96","author":"JK Hiller","year":"2017","unstructured":"Hiller JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, Yalcin A, Abdelkarim M, Blagitko-Dorfs N, Dohner K, Bullinger L, Duyster J et al (2017) Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy. Ann Hematol 96(4):559\u2013565","journal-title":"Ann Hematol"},{"issue":"5","key":"7137_CR18","doi-asserted-by":"publisher","first-page":"E77","DOI":"10.1002\/ajh.23965","volume":"90","author":"A Emadi","year":"2015","unstructured":"Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA (2015) Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol 90(5):E77-79","journal-title":"Am J Hematol"},{"issue":"7","key":"7137_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/leu.2011.71","volume":"25","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S et al (2011) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25(7):1147\u20131152","journal-title":"Leukemia"},{"issue":"7","key":"7137_CR20","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, Lubbert M (2021) Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35(7):1873\u20131889","journal-title":"Leukemia"},{"key":"7137_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells7090138","author":"MD Merkerova","year":"2018","unstructured":"Merkerova MD, Remesova H, Krejcik Z, Loudova N, Hrustincova A, Szikszai K, Cermak J, Jonasova A, Belickova M (2018) Relationship between altered miRNA expression and DNA methylation of the DLK1-DIO3 region in azacitidine-treated patients with myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. Cells. 14;7(9):138. https:\/\/doi.org\/10.3390\/cells7090138","journal-title":"Cells"},{"issue":"5","key":"7137_CR22","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1172\/JCI78752","volume":"125","author":"K Meldi","year":"2015","unstructured":"Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Micol JB, Selimoglu-Buet D, Masala E, Allione B, Gioia D et al (2015) Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest 125(5):1857\u20131872","journal-title":"J Clin Invest"},{"key":"7137_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1438052","volume":"14","author":"MDR Gonzalez","year":"2024","unstructured":"Gonzalez MDR, Chakraborty S, Hernandez-Sanchez JM, Diez Campelo M, Park CY, Hernandez Rivas JM (2024) Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response. Front Oncol 14:1438052","journal-title":"Front Oncol"},{"key":"7137_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9:559","journal-title":"BMC Bioinformatics"},{"key":"7137_CR25","doi-asserted-by":"publisher","DOI":"10.2202\/1544-6115.1128","volume":"4","author":"B Zhang","year":"2005","unstructured":"Zhang B, Horvath S (2005) A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 4:Article17","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"Database issue","key":"7137_CR26","doi-asserted-by":"publisher","first-page":"D1049","DOI":"10.1093\/nar\/gku1179","volume":"43","author":"Gene Ontology C","year":"2015","unstructured":"Gene Ontology C (2015) Gene ontology consortium: going forward. Nucleic Acids Res 43(Database issue):D1049-1056","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"7137_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1):27\u201330","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"7137_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT et al (2000) <article-title update=\"added\">Gene ontology: tool for the unification of biology. Nat Genet 25(1):25\u201329","journal-title":"Nat Genet"},{"issue":"Database issue","key":"7137_CR29","doi-asserted-by":"publisher","first-page":"D428","DOI":"10.1093\/nar\/gki072","volume":"33","author":"G Joshi-Tope","year":"2005","unstructured":"Joshi-Tope G, Gillespie M, Vastrik I, D\u2019Eustachio P, Schmidt E, de Bono B, Jassal B, Gopinath GR, Wu GR, Matthews L et al (2005) Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 33(Database issue):D428\u2013432","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"7137_CR30","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G et al (2014) TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124(17):2705\u20132712","journal-title":"Blood"},{"issue":"5","key":"7137_CR31","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12185-016-2058-3","volume":"104","author":"M Monika Belickova","year":"2016","unstructured":"Monika Belickova M, Merkerova MD, Votavova H, Valka J, Vesela J, Pejsova B, Hajkova H, Klema J, Cermak J, Jonasova A (2016) Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms. Int J Hematol 104(5):566\u2013573","journal-title":"Int J Hematol"},{"issue":"11","key":"7137_CR32","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.3324\/haematol.2016.148999","volume":"101","author":"CC Coombs","year":"2016","unstructured":"Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS et al (2016) Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica 101(11):e457\u2013e460","journal-title":"Haematologica"},{"issue":"2","key":"7137_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.leukres.2012.10.015","volume":"37","author":"R Claus","year":"2013","unstructured":"Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C, Lubbert M (2013) Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leuk Res 37(2):190\u2013196","journal-title":"Leuk Res"},{"issue":"4","key":"7137_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1158\/0008-5472.CAN-20-1430","volume":"81","author":"G Greve","year":"2021","unstructured":"Greve G, Schuler J, Gruning BA, Berberich B, Stomper J, Zimmer D, Gutenkunst L, Bonisch U, Meier R, Blagitko-Dorfs N et al (2021) Decitabine induces gene derepression on monosomic chromosomes: in vitro and in vivo effects in adverse-risk cytogenetics AML. Cancer Res 81(4):834\u2013846","journal-title":"Cancer Res"},{"issue":"43","key":"7137_CR35","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43):15545\u201315550","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"7137_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/j.seminhematol.2019.02.001","volume":"56","author":"J Stomper","year":"2019","unstructured":"Stomper J, Lubbert M (2019) Can we predict responsiveness to hypomethylating agents in AML? Semin Hematol 56(2):118\u2013124","journal-title":"Semin Hematol"},{"key":"7137_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0237-y","volume":"8","author":"J Diesch","year":"2016","unstructured":"Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Gotze KS (2016) A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics 8:71","journal-title":"Clin Epigenetics"},{"issue":"12","key":"7137_CR38","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1158\/1078-0432.CCR-08-2783","volume":"15","author":"JP Issa","year":"2009","unstructured":"Issa JP, Kantarjian HM (2009) Targeting DNA methylation. Clin Cancer Res 15(12):3938\u20133946","journal-title":"Clin Cancer Res"},{"issue":"4","key":"7137_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.exphem.2013.12.004","volume":"42","author":"P Sripayap","year":"2014","unstructured":"Sripayap P, Nagai T, Uesawa M, Kobayashi H, Tsukahara T, Ohmine K, Muroi K, Ozawa K (2014) Mechanisms of resistance to azacitidine in human leukemia cell lines. Exp Hematol 42(4):294-306 e292","journal-title":"Exp Hematol"},{"issue":"1","key":"7137_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02961-3","volume":"23","author":"S Okabe","year":"2023","unstructured":"Okabe S, Tanaka Y, Moriyama M, Gotoh A (2023) WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment. Cancer Cell Int 23(1):128","journal-title":"Cancer Cell Int"},{"key":"7137_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0053-9","volume":"7","author":"W Qi","year":"2014","unstructured":"Qi W, Xie C, Li C, Caldwell JT, Edwards H, Taub JW, Wang Y, Lin H, Ge Y (2014) CHK1 plays a critical role in the anti-leukemic activity of the WEE1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol 7:53","journal-title":"J Hematol Oncol"},{"issue":"4","key":"7137_CR42","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3324\/haematol.2013.093187","volume":"99","author":"L Chaudhuri","year":"2014","unstructured":"Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA et al (2014) CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica 99(4):688\u2013696","journal-title":"Haematologica"},{"issue":"1","key":"7137_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00361-x","volume":"5","author":"JL Carter","year":"2020","unstructured":"Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, Huttemann M, Taub JW, Ge Y (2020) Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther 5(1):288","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"7137_CR44","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2009-08-240101","volume":"115","author":"JA Pulikkan","year":"2010","unstructured":"Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK, Tenen DG, Behre G (2010) Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 115(9):1768\u20131778","journal-title":"Blood"},{"issue":"15","key":"7137_CR45","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood-2013-07-511683","volume":"123","author":"L Rishi","year":"2014","unstructured":"Rishi L, Hannon M, Salome M, Hasemann M, Frank AK, Campos J, Timoney J, O\u2019Connor C, Cahill MR, Porse B et al (2014) Regulation of Trib2 by an E2F1-C\/EBPalpha feedback loop in AML cell proliferation. Blood 123(15):2389\u20132400","journal-title":"Blood"},{"issue":"10","key":"7137_CR46","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.1038\/cddis.2012.151","volume":"3","author":"B Salvatori","year":"2012","unstructured":"Salvatori B, Iosue I, Mangiavacchi A, Loddo G, Padula F, Chiaretti S, Peragine N, Bozzoni I, Fazi F, Fatica A (2012) The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. Cell Death Dis 3(10):e413","journal-title":"Cell Death Dis"},{"issue":"3","key":"7137_CR47","doi-asserted-by":"publisher","first-page":"e1152","DOI":"10.1038\/cddis.2014.112","volume":"5","author":"A Sheth","year":"2014","unstructured":"Sheth A, Escobar-Alvarez S, Gardner J, Ran L, Heaney ML, Scheinberg DA (2014) Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death Dis 5(3):e1152","journal-title":"Cell Death Dis"},{"issue":"8","key":"7137_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105381","volume":"9","author":"XN Pan","year":"2014","unstructured":"Pan XN, Chen JJ, Wang LX, Xiao RZ, Liu LL, Fang ZG, Liu Q, Long ZJ, Lin DJ (2014) Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation. PLoS One 9(8):e105381","journal-title":"PLoS One"},{"key":"7137_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076816","author":"H Long","year":"2023","unstructured":"Long H, Hou Y, Li J, Song C, Ge Z (2023) Azacitidine is synergistically lethal with XPO1 inhibitor selinexor in acute myeloid leukemia by targeting XPO1\/eIF4E\/c-MYC signaling. Int J Mol Sci 6;24(7):6816. https:\/\/doi.org\/10.3390\/ijms24076816","journal-title":"Int J Mol Sci"},{"issue":"4","key":"7137_CR50","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s10637-022-01251-5","volume":"40","author":"Y Guo","year":"2022","unstructured":"Guo Y, Liu Z, Duan L, Shen H, Ding K, Fu R (2022) Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation. Invest New Drugs 40(4):738\u2013746","journal-title":"Invest New Drugs"},{"issue":"17","key":"7137_CR51","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood-2014-10-607648","volume":"125","author":"P Ranganathan","year":"2015","unstructured":"Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA et al (2015) Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood 125(17):2689\u20132692","journal-title":"Blood"},{"issue":"2","key":"7137_CR52","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/10428194.2019.1665664","volume":"61","author":"B Bhatnagar","year":"2020","unstructured":"Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS et al (2020) Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma 61(2):387\u2013396","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"7137_CR53","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3026(20)30209-X","volume":"7","author":"J Taylor","year":"2020","unstructured":"Taylor J, Mi X, Penson AV, Paffenholz SV, Alvarez K, Sigler A, Chung SS, Rampal RK, Park JH, Stein EM et al (2020) Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Lancet Haematol 7(8):e566\u2013e574","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07137-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07137-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07137-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:06:34Z","timestamp":1791673594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07137-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7137"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07137-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"410"}}